Ergomed - Robust performance in 2022

Davy Research
/Read Important Disclosures

Ergomed has released detailed FY 22 results following its trading update on January 31st, reflecting strong revenue growth and stable service fee gross profit margins. Expansion in the orderbook provides visibility for growth in the next year. The balance sheet is net cash, providing optionality on acquisition growth.